By-health Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100000Y84
CNY
9.71
-0.06 (-0.61%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

13.2 M

Shareholding (Jun 2017)

FII

0.02%

Held by 1 FIIs

DII

99.98%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

The company has declared Positive results for the last 3 consecutive quarters

  • NET PROFIT(9M) At CNY 401.27 MM has Grown at 89.31%
  • RAW MATERIAL COST(Y) Fallen by -4.8% (YoY)
  • CASH AND EQV(HY) Highest at CNY 12,265.47 MM
2

With ROE of 6.14%, it has a fair valuation with a 1.74 Price to Book Value

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CNY 11,491 Million (Large Cap)

stock-summary
P/E

28.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

6.66%

stock-summary
Debt Equity

-0.43

stock-summary
Return on Equity

5.95%

stock-summary
Price to Book

1.00

Revenue and Profits:
Net Sales:
1,869 Million
(Quarterly Results - Mar 2026)
Net Profit:
403 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-19.49%
0%
-19.49%
6 Months
-20.54%
0%
-20.54%
1 Year
-16.51%
0%
-16.51%
2 Years
-36.91%
0%
-36.91%
3 Years
-58.4%
0%
-58.4%
4 Years
-48.43%
0%
-48.43%
5 Years
-73.9%
0%
-73.9%

By-health Co., Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0.52%
EBIT Growth (5y)
66.71%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.58
Tax Ratio
29.36%
Dividend Payout Ratio
96.38%
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
21.48%
ROE (avg)
14.00%

Valuation key factors

Factor
Value
P/E Ratio
28
Industry P/E
Price to Book Value
1.74
EV to EBIT
17.44
EV to EBITDA
13.99
EV to Capital Employed
2.24
EV to Sales
2.51
PEG Ratio
2.40
Dividend Yield
3.11%
ROCE (Latest)
12.82%
ROE (Latest)
6.14%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Bearish
Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2017stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.02%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 4.30% vs -31.99% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -13.61% vs -35.10% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,868.80",
          "val2": "1,791.70",
          "chgp": "4.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "442.50",
          "val2": "603.40",
          "chgp": "-26.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.60",
          "val2": "4.50",
          "chgp": "-42.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "20.30",
          "val2": "13.20",
          "chgp": "53.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "403.10",
          "val2": "466.60",
          "chgp": "-13.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "236.80%",
          "val2": "295.30%",
          "chgp": "-5.85%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -8.63% vs -26.93% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 26.04% vs -63.58% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6,218.40",
          "val2": "6,805.50",
          "chgp": "-8.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,178.80",
          "val2": "998.80",
          "chgp": "18.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "15.80",
          "val2": "13.80",
          "chgp": "14.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "27.70",
          "val2": "28.00",
          "chgp": "-1.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "816.60",
          "val2": "647.90",
          "chgp": "26.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "142.90%",
          "val2": "109.20%",
          "chgp": "3.37%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoYstock-summary

Mar'26
Mar'25
Change(%)
Net Sales
1,868.80
1,791.70
4.30%
Operating Profit (PBDIT) excl Other Income
442.50
603.40
-26.67%
Interest
2.60
4.50
-42.22%
Exceptional Items
20.30
13.20
53.79%
Consolidate Net Profit
403.10
466.60
-13.61%
Operating Profit Margin (Excl OI)
236.80%
295.30%
-5.85%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Mar 2026 is 4.30% vs -31.99% in Mar 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is -13.61% vs -35.10% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
6,218.40
6,805.50
-8.63%
Operating Profit (PBDIT) excl Other Income
1,178.80
998.80
18.02%
Interest
15.80
13.80
14.49%
Exceptional Items
27.70
28.00
-1.07%
Consolidate Net Profit
816.60
647.90
26.04%
Operating Profit Margin (Excl OI)
142.90%
109.20%
3.37%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is -8.63% vs -26.93% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 26.04% vs -63.58% in Dec 2024

stock-summaryCompany CV
About By-health Co., Ltd. stock-summary
stock-summary
By-health Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available